Amgen, Inc. (AMGN)’s Future Is Bright

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has a bio-similar version of Neupogen, which was approved by the FDA in August of 2012. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has already launched in Europe, but will have to wait to launch the drug in the United States. The reason being is because Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) entered into an agreement with Amgen to be able to launch the biosimilar drug in November 2013. This is just a bit of time before Amgen’s patent expiration on the Neupogen drug.

Final thoughts

Amgen is an outstanding company with many drugs that have made it billions over the years. The company is specialized in many areas of the biotech sector, and has been able to acquire companies as well to expand its pipeline. For instance the acquisition of Immunex back in 2003, which allowed Amgen to be able to sell Enbrel in the open market. These blockbuster drugs continue to make billions for the company for the foreseeable future, as there is limited competition.

Pfizer will be a big competitor going forward, but Amgen, Inc. (NASDAQ:AMGN) has the pipeline to be able to compete. Affymax, Inc. (OTCMKTS:AFFY) is no longer a problem in terms of competition, because of the company having to remove Omontys off the market for the time being. Amgen will continue to acquire small-cap biotech companies that fits in with its long-term plan. Also, Amgen has pumped some money into another small-cap biotech stock, because of the potential value, known as Cytokinetics, Inc. (NASDAQ:CYTK). Cytokinetics, Inc. (NASDAQ:CYTK) has trials going for heart failure, and ALS, commonly called Lou Gehrig’s disease. Going forward, long-term investors have plenty to be happy about as Amgen’s future is very bright!

The article Amgen’s Future Is Bright originally appeared on Fool.com and is written by Terry Chrisomalis.

Terry Chrisomalis has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Terry is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.